| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2288 | 2019 |
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype S Turcan, D Rohle, A Goenka, LA Walsh, F Fang, E Yilmaz, C Campos, ... Nature 483 (7390), 479-483, 2012 | 2117 | 2012 |
| Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies S Veeriah, BS Taylor, S Meng, F Fang, E Yilmaz, I Vivanco, ... Nature genetics 42 (1), 77-82, 2010 | 415 | 2010 |
| MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors AJ Luna, RT Sterk, AM Griego-Fisher, JY Chung, KL Berggren, V Bondu, ... PLoS pathogens 17 (1), e1009216, 2021 | 26 | 2021 |
| Emerging treatment for advanced lung cancer with EGFR mutation C Inal, E Yilmaz, B Piperdi, R Perez-Soler, H Cheng Expert Opinion on Emerging Drugs 20 (4), 597-612, 2015 | 26 | 2015 |
| Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers: ASCO guideline E Yilmaz, N Ismaila, JE Bauman, R Dabney, G Gan, R Jordan, M Kaufman, ... Journal of Clinical Oncology 41 (5), 1132-1146, 2023 | 25 | 2023 |
| Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center. C Inal, E Yilmaz, H Cheng, C Zhu, J Pullman, RA Gucalp, SM Keller, ... Journal of Clinical Oncology 32 (15_suppl), 8098-8098, 2014 | 21 | 2014 |
| PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer D De Martino, E Yilmaz, A Orlacchio, M Ranieri, K Zhao, A Di Cristofano Cancer letters 439, 56-65, 2018 | 19 | 2018 |
| First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2, 3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 … TA Yap, S Sahebjam, DS Hong, VK Chiu, E Yilmaz, S Efuni, ... Journal of Clinical Oncology 36 (15_suppl), 3040-3040, 2018 | 14 | 2018 |
| Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. GJ Hanna, JM Kaczmar, DP Zandberg, DJL Wong, E Yilmaz, EJ Sherman, ... Journal of Clinical Oncology 41 (16_suppl), 6005-6005, 2023 | 10 | 2023 |
| Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). AL Coveler, DL Bajor, A Masood, E Yilmaz, AF Shields, MM Javle, ... Journal of Clinical Oncology 38 (15_suppl), TPS4671-TPS4671, 2020 | 10 | 2020 |
| Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: a case report with treatment implications and review of literature M Torrez, RC Braunberger, E Yilmaz, S Agarwal Pathology-Research and Practice 216 (10), 153146, 2020 | 9 | 2020 |
| Association of treatment strategies and tumor characteristics with overall survival among patients with anaplastic thyroid cancer: a single-institution 21-year experience SS Wu, ED Lamarre, A Yalamanchali, PR Brauer, H Hong, CA Reddy, ... JAMA Otolaryngology–Head & Neck Surgery 149 (4), 300-309, 2023 | 8 | 2023 |
| Immunotherapy in HPV-related oropharyngeal cancers L Roof, E Yilmaz Current Treatment Options in Oncology 24 (3), 170-183, 2023 | 8 | 2023 |
| Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid … C Muller, UA Brown-Glaberman, MF Chaney, T Garyantes, P LoRusso, ... Journal of Clinical Oncology 39 (15_suppl), 3084-3084, 2021 | 8 | 2021 |
| NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck … JE Bauman, J Harris, R Uppaluri, M Yao, RL Ferris, J Chen, RC Jordan, ... Journal of Clinical Oncology 37 (15_suppl), 6023-6023, 2019 | 8 | 2019 |
| NRG-HN003: Phase I and expansion cohort study of adjuvant pembrolizumab, cisplatin and radiation therapy in pathologically high-risk head and neck cancer JE Bauman, J Harris, R Uppaluri, M Yao, RL Ferris, J Chen, RC Jordan, ... Cancers 13 (12), 2882, 2021 | 7 | 2021 |
| Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202. P Swiecicki, E Yilmaz, AJ Rosenberg, T Fujisawa, J Yang Bruce, C Meng, ... Journal of Clinical Oncology 41 (16_suppl), 6017-6017, 2023 | 4 | 2023 |
| Lachnoclostridium and immune inflamed gene expression signature association in head & neck cancers E Yilmaz, A Yalamanchali, ME Dwidar, JL Geiger, S Koyfman, TA Chan, ... International Journal of Radiation Oncology, Biology, Physics 112 (5), e37, 2022 | 4 | 2022 |
| A 45-year history of acquired autoimmune neuromyotonia A Ryan, G Mullins, J Scott, S Connolly, O Hardiman, E Yilmaz, A Vincent, ... Journal of neurology 253, 1243-1245, 2006 | 4 | 2006 |
